Physician profile
Daniel J Skarzynski
NPI 1104988583
$1,966.21
in general payments reported to CMS, 2019-2025
30 companies · $364 in 2025
The $364 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $262 · 2021: $48.33 · 2022: $169 · 2023: $245 · 2024: $273 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $267.59 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $236.72 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $225.95 | 2019-2023 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $220.39 | 2019-2025 | |
| Shockwave Medical, INC | $170.55 | 2021-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $85.29 | 2019-2020 | |
| Cordis US Corp. | $62.93 | 2024-2025 | Mynx Control, Mynx Control Venous, Infiniti |
| Penumbra, INC. | $59.23 | 2023-2025 | Indigo System, Penumbra System |
| Irhythm Technologies, INC. | $56.81 | 2019 | |
| Janssen Pharmaceuticals, INC | $52.30 | 2019-2020 | |
| Abbott Laboratories | $52.15 | 2019-2024 | Perclose Proglide |
| Inari Medical, INC. | $49.46 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Sanofi-Aventis U.S. LLC | $46.77 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $43.61 | 2019-2022 | |
| Medtronic, INC. | $42.75 | 2025 | Symplicity G3, Attain Command + Surevalve |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $40.78 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $29.62 | 2019 | |
| Amarin Pharma, INC. | $26.83 | 2019 | |
| Edwards Lifesciences Corporation | $26.51 | 2024 | Sapien 3 Ultra Resilia |
| Medtronic Vascular, INC. | $25.33 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $20.47 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.25 | 2019 | |
| Kls-Martin L.P. | $15.81 | 2019 | |
| Akcea Therapeutics, INC. | $15.25 | 2020 | |
| Terumo Medical Corporation | $14.23 | 2020 | |
| Astellas Pharma US INC | $14.00 | 2019 | |
| Pfizer INC. | $12.66 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.56 | 2020 | |
| Medela LLC | $11.99 | 2020 | |
| Cardinal Health 200 LLC | $11.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Skarzynski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.